Lotus Eye Hospit

Why is Lotus Eye Hospital & Institute Ltd falling/rising?

As of 23-Jun, the stock price of Lotus Eye Hospital & Institute Ltd is Rs 123.80, down 3.32%, with a significant 11.54% drop over the past week and reduced investor participation. This indicates current downward pressure despite a strong long-term performance.

As of 23-Jun, the stock price of Lotus Eye Hospital & Institute Ltd is falling, currently at Rs 123.80, which reflects a decrease of Rs 4.25 or 3.32%. This decline is evident in the stock's performance today, where it underperformed its sector by 4.2%. The stock also touched an intraday low of Rs 123, marking a decrease of 3.94%.<BR><BR>In terms of recent trends, the stock has shown a significant drop of 11.54% over the past week, contrasting sharply with the Sensex, which only fell by 0.79% during the same period. Additionally, there has been a notable decline in investor participation, with delivery volume on June 22 dropping by 80.36% compared to the 5-day average. This reduced trading activity suggests a lack of confidence among investors, contributing to the stock's downward movement.<BR><BR>Despite a positive performance over longer periods, such as a 75.60% increase over the past year, the current short-term trends and decreased investor engagement indicate that the stock is facing downward pressure at this time.

Which are the latest news on Lotus Eye Hospit?

What does Lotus Eye Hospit do?

Lotus Eye Hospital & Institute Ltd specializes in ophthalmic care and operates as a micro-cap company. As of March 2026, it reported net sales of 14 Cr and a market cap of INR 264 Cr.

Overview:<BR>Lotus Eye Hospital & Institute Ltd operates in the hospital industry as a micro-cap company, specializing in ophthalmic care.<BR><BR>History:<BR>The company was originally incorporated as "Kalaivani Health Centre Pvt. Limited" in 1997. It underwent several name changes, becoming "Lotus Eye Care Hospital Pvt. Limited" in 2006, and was converted into a Public Limited Company in 2007. The current name, Lotus Eye Hospital & Institute Limited, was adopted in 2013. The most recent quarterly results reported net sales and net profit for March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 14 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 264 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 2,804.00<BR>- Industry P/E: 60<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.20<BR>- Return on Equity: 0.15%<BR>- Price to Book: 4.22<BR><BR>Contact Details:<BR>- Address: SF No770/12 Civil Aerodrome(P), Avinashi Road Coimbatore Tamil Nadu : 641014<BR>- Tel: 91-0422 4229900<BR>- Email: lotussecdept@gmail.com<BR>- Website: http://www.lotuseye.org

How big is Lotus Eye Hospit?

As of 10th June, Lotus Eye Hospital & Institute Ltd has a market capitalization of 264.00 Cr, with recent net sales of 53.72 Cr and a net profit of 0.08 Cr. Shareholder's funds are 60.00 Cr, and total assets amount to 69.49 Cr.

As of 10th June, the company name is Lotus Eye Hospital & Institute Ltd, with a market capitalization of 264.00 Cr, classified as a Micro Cap.<BR><BR>In the latest 4 quarters, the company reported Net Sales of 53.72 Cr and a Net Profit of 0.08 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 60.00 Cr and Total Assets of 69.49 Cr.

Who are in the management team of Lotus Eye Hospit?

The management team of Lotus Eye Hospital includes S K Sundaramoorthy (Chairman cum Managing Director), Sangeetha Sundaramoorthy (Whole Time Director), and several Non-Executive Independent Directors, along with a Company Secretary. This diverse team brings a wealth of expertise to the hospital's management.

The management team of Lotus Eye Hospital includes the following key members:<BR><BR>1. **S K Sundaramoorthy** - Chairman cum Managing Director<BR>2. **Sangeetha Sundaramoorthy** - Whole Time Director<BR>3. **Kavetha Sundaramoorthy** - Promoter & Non-Executive Director<BR>4. **S S Badrinath** - Non-Executive Independent Director<BR>5. **D R Kaarthikeyan** - Non-Executive Independent Director<BR>6. **Yogesh Shah** - Non-Executive Independent Director<BR>7. **G R Karthikeyan** - Non-Executive Independent Director<BR>8. **R Subramanian** - Non-Executive Independent Director<BR>9. **M Alagiriswamy** - Non-Executive Independent Director<BR>10. **PR Rangaswami** - Alternate Director to Kavetha Sundaramoorthy<BR>11. **Aakanksha Parmar** - Company Secretary & Compliance Officer<BR><BR>This diverse team brings a range of expertise to the management of the hospital.

Who are the peers of the Lotus Eye Hospit?

Lotus Eye Hospit's peers include Asarfi Hospital, Aashka Hospitals, and others, with varying management risks and growth rates. Lotus Eye Hospit has a Below Average management risk and growth, while its 1-year return of 66.04% exceeds that of its peers.

Peers: The peers of Lotus Eye Hospit are Asarfi Hospital, Aashka Hospitals, Abate As Indust, Aprameya Enginee, Vaidya Sane, Chandan Healthca, Unihealth Hosp, and KHFM Hospitality.<BR><BR>Quality Snapshot: Excellent management risk is observed at Aprameya Enginee, while Average management risk is found at Asarfi Hospital, Vaidya Sane, and Chandan Healthca, and the rest. Below Average management risk is present at Lotus Eye Hospit, Aashka Hospitals, Abate As Indust, and KHFM Hospitality. Growth is Excellent at Chandan Healthca and Unihealth Hosp, Average at Vaidya Sane, and the rest, while Below Average growth is noted at Lotus Eye Hospit, Aashka Hospitals, Abate As Indust, and KHFM Hospitality. Good capital structure is seen at Asarfi Hospital, Aprameya Enginee, Vaidya Sane, Chandan Healthca, and Unihealth Hosp, while Average capital structure is found at Aashka Hospitals and Abate As Indust, and Below Average at KHFM Hospitality.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Asarfi Hospital at 64.21%, while the lowest is Aashka Hospitals at -24.05%. Lotus Eye Hospit has a 1-year return of 66.04%, which is higher than Asarfi Hospital's return. Additionally, Abate As Indust and KHFM Hospitality have negative six-month returns.

Should I buy, sell or hold Lotus Eye Hospital & Institute Ltd?

Are Lotus Eye Hospital & Institute Ltd latest results good or bad?

Lotus Eye Hospital & Institute Ltd's latest results are concerning, showing an 18.25% increase in revenue to ₹13.61 crores but a net loss of ₹0.32 crores, indicating significant operational challenges and declining profitability. Despite revenue growth, the company's deteriorating margins and low return on equity suggest a poor overall performance.

Lotus Eye Hospital & Institute Ltd's latest results indicate a challenging situation for the company. In the fourth quarter of FY26, they reported net sales of ₹13.61 crores, which is an 18.25% increase year-on-year and the highest quarterly revenue in their history. However, this revenue growth has not translated into profitability, as the company posted a net loss of ₹0.32 crores, a significant decline compared to a profit of ₹0.25 crores in the same quarter last year.<BR><BR>The operating margin has also deteriorated sharply, falling to just 3.53% from 10.95% in the first quarter of FY26. This decline raises concerns about the company's operational efficiency, especially in a competitive market like eye care in India. Additionally, the return on equity (ROE) stands at a mere 1.07%, which is well below industry standards, further highlighting the company's struggles to generate adequate returns on shareholder capital.<BR><BR>Overall, while the revenue growth is a positive sign, the inability to achieve profitability and the significant margin compression suggest that the results are more indicative of underlying operational issues rather than a strong performance. Therefore, the latest results can be characterized as bad, reflecting critical profitability concerns and operational challenges.

How has been the historical performance of Lotus Eye Hospit?

Lotus Eye Hospital has experienced revenue growth from INR 32.37 crore in March 2021 to INR 49.56 crore in March 2025, but profitability has declined, with profit after tax dropping from INR 4.08 crore to INR 0.74 crore during the same period, alongside decreasing cash flow. Total assets and liabilities have both increased, indicating financial strain despite rising sales.

Answer:<BR>The historical performance of Lotus Eye Hospital shows a mixed trend over the years, with fluctuations in revenue and profit metrics.<BR><BR>Breakdown:<BR>Lotus Eye Hospital's net sales have shown a steady increase from INR 32.37 crore in March 2021 to INR 49.56 crore in March 2025, with a notable rise from INR 38.91 crore in March 2022. Total operating income has mirrored this trend, reaching INR 49.56 crore in March 2025. However, the total expenditure has also increased significantly, from INR 28.81 crore in March 2021 to INR 46.13 crore in March 2025, impacting operating profit, which fell from INR 7.58 crore in March 2023 to INR 3.43 crore in March 2025. Consequently, profit before tax decreased from INR 5.65 crore in March 2023 to INR 1.38 crore in March 2025, with profit after tax also declining from INR 4.08 crore to INR 0.74 crore during the same period. The company's total assets rose from INR 57.26 crore in March 2020 to INR 69.49 crore in March 2025, while total liabilities increased from INR 58.46 crore to INR 69.49 crore. Cash flow from operating activities decreased from INR 5 crore in March 2024 to INR 2 crore in March 2025, contributing to a net cash outflow of INR 5 crore in March 2025, compared to a net outflow of INR 2 crore in March 2024. Overall, while revenue has grown, profitability and cash flow have faced challenges in recent years.

Is Lotus Eye Hospit overvalued or undervalued?

As of May 30, 2025, Lotus Eye Hospital & Institute Ltd. is considered very expensive and overvalued, with a high PE ratio of 148.28 and a low return on equity of 1.21%, indicating that its current stock price of 74.41 is not justified despite strong past stock performance.

As of 30 May 2025, the valuation grade for Lotus Eye Hospital & Institute Ltd. has moved from risky to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, as evidenced by its high PE ratio of 148.28, an EV to EBIT of 143.74, and an EV to EBITDA of 41.66, which are substantially above industry norms. <BR><BR>When compared to its peers, Lotus Eye Hospital's valuation metrics stand out unfavorably; for instance, its PE ratio is significantly higher than the industry average, suggesting that investors are paying a premium for its earnings. Additionally, the company's return on equity (ROE) is a mere 1.21%, which raises concerns about its profitability relative to its valuation. Despite a strong performance in stock returns over the past year, outpacing the Sensex, the current valuation metrics suggest that the stock is not justified at its current price of 74.41.

What is the technical trend for Lotus Eye Hospit?

As of June 4, 2025, Lotus Eye Hospital's technical trend is mildly bullish, supported by a bullish weekly MACD and Bollinger Bands, despite mixed signals from monthly indicators and a mildly bearish weekly Dow Theory.

As of 4 June 2025, the technical trend for Lotus Eye Hospit has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, supporting a positive outlook. Daily moving averages are also mildly bullish. However, the Dow Theory shows a mildly bearish stance on the weekly chart, contrasting with a mildly bullish monthly view. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD and Bollinger Bands, despite some bearish signals in the monthly indicators.

Who are the top shareholders of the Lotus Eye Hospit?

The top shareholders of Lotus Eye Hospital are Sangeetha S with 18.95%, followed by Kovai Purani Finance Private Limited at 6.67%. Individual investors hold a combined 40.95%, with no mutual funds or foreign institutional investors involved, and no pledged promoter holdings.

The top shareholders of Lotus Eye Hospital include Sangeetha S, who holds the largest stake at 18.95%. Following her, Kovai Purani Finance Private Limited is the highest public shareholder with a 6.67% ownership. Additionally, individual investors collectively hold 40.95% of the shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

When is the next results date for Lotus Eye Hospit?

No Upcoming Board Meetings

Has Lotus Eye Hospit declared dividend?

Lotus Eye Hospital & Institute Ltd has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of September 18, 2023. Despite the dividend declaration, the dividend yield is 0%, and total returns have varied across different periods, showing significant gains over the long term.

Lotus Eye Hospital & Institute Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 18 Sep 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -3.66%, the dividend return was 0%, resulting in a total return of -3.66%.<BR><BR>For the 1-year period, the price return was 26.61%, the dividend return was 0%, leading to a total return of 26.61%.<BR><BR>Over the 2-year period, the price return was -7.97%, the dividend return was 0.62%, resulting in a total return of -7.35%.<BR><BR>In the 3-year period, the price return was 46.37%, the dividend return was 1.99%, culminating in a total return of 48.36%.<BR><BR>For the 4-year period, the price return was 53.89%, the dividend return was 2.77%, leading to a total return of 56.66%.<BR><BR>In the 5-year period, the price return was 199.28%, the dividend return was 4.76%, resulting in a total return of 204.04%.<BR><BR>Overall, while Lotus Eye Hospital & Institute Ltd has declared a dividend, the dividend yield remains at 0%. The total returns over various periods show a mixed performance, with significant gains over longer periods, particularly in the 5-year span.